Evidence map›Paper›PMID 38727269›Full record

ArticleCells2024

Valproic Acid Treatment after Traumatic Brain Injury in Mice Alleviates Neuronal Death and Inflammation in Association with Increased Plasma Lysophosphatidylcholines.

Regina Hummel, Erika Dorochow, Sonja Zander, Katharina Ritter, Lisa Hahnefeld, Robert Gurke, Irmgard Tegeder, Michael K E Schäfer

Abstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Post-Translational Modifications in Traumatic Brain Injury: Decoding the Proteomic Landscape and Molecular Mechanisms of Secondary Injury.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Regina HummelDepartment of Anesthesiology, University Medical Center Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.ORCID 0000-0002-7223-2703
Erika DorochowInstitute of Clinical Pharmacology, Medical Faculty, Goethe-University Frankfurt, 60596 Frankfurt am Main, Germany.ORCID 0000-0002-0383-3273
Sonja ZanderDepartment of Anesthesiology, University Medical Center Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
Katharina RitterDepartment of Anesthesiology, University Medical Center Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
Lisa HahnefeldInstitute of Clinical Pharmacology, Medical Faculty, Goethe-University Frankfurt, 60596 Frankfurt am Main, Germany.ORCID 0000-0002-0382-5695
Robert GurkeInstitute of Clinical Pharmacology, Medical Faculty, Goethe-University Frankfurt, 60596 Frankfurt am Main, Germany.
Irmgard TegederInstitute of Clinical Pharmacology, Medical Faculty, Goethe-University Frankfurt, 60596 Frankfurt am Main, Germany.ORCID 0000-0001-7524-8025
Michael K E SchäferDepartment of Anesthesiology, University Medical Center Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.ORCID 0000-0001-6055-6244

Funding

Deutsche Forschungsgemeinschaft CRC1039, project A3 to IT, project Z and 445757098 to RG
6 · The paper itself

Abstract

The histone deacetylase inhibitor (HDACi) valproic acid (VPA) has neuroprotective and anti-inflammatory effects in experimental traumatic brain injury (TBI), which have been partially attributed to the epigenetic disinhibition of the transcription repressor RE1-Silencing Transcription Factor/Neuron-Restrictive Silencer Factor (REST/NRSF). Additionally, VPA changes post-traumatic brain injury (TBI) brain metabolism to create a neuroprotective environment. To address the interconnection of neuroprotection, metabolism, inflammation and REST/NRSF after TBI, we subjected C57BL/6N mice to experimental TBI and intraperitoneal VPA administration or vehicle solution at 15 min, 1, 2, and 3 days post-injury (dpi). At 7 dpi, TBI-induced an up-regulation of REST/NRSF gene expression and HDACi function of VPA on histone H3 acetylation were confirmed. Neurological deficits, brain lesion size, blood-brain barrier permeability, or astrogliosis were not affected, and REST/NRSF target genes were only marginally influenced by VPA. However, VPA attenuated structural damage in the hippocampus, microgliosis and expression of the pro-inflammatory marker genes. Analyses of plasma lipidomic and polar metabolomic patterns revealed that VPA treatment increased lysophosphatidylcholines (LPCs), which were inversely associated with interleukin 1 beta (

Indexed as

Brain Injuries, TraumaticInflammationLysophosphatidylcholinesMice, Inbred C57BLNeuronsValproic AcidAnimalsCell DeathDisease Models, AnimalHistone Deacetylase InhibitorsMaleMiceNeuroprotective AgentsRE1-Silencing Transcription FactorRepressor ProteinsHistone Deacetylase InhibitorsLysophosphatidylcholinesNeuroprotective AgentsRE1-Silencing Transcription FactorRepressor ProteinsValproic Acidlipidomic and metabolomic analyseslysophoshatidylcholineneuroinflammationthreonic acidtraumatic brain injuryvalproic acid

Identifiers

PMID38727269
PMCPMC11083124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.